Need for Policy Reforms in the Aftermath of COVID-19? An Analysis of Indian Pharmaceutical Sector

Author:

Banik Nilanjan1,Chakraborty Debashis2ORCID,Dash Sampada Kumar3

Affiliation:

1. School of Management, Mahindra University, Hyderabad, Telangana, India

2. Indian Institute of Foreign Trade, Kolkata, West Bengal, India

3. Pharmaceutical and Healthcare Vertical, New Delhi, India

Abstract

Acknowledging coronavirus disease 2019 (COVID-19) as a persistent health challenge in the foreseeable future, there is a need to evaluate how India can emerge as a major exporter in this category. This analysis with 41 COVID-19-related pharmaceutical products indicates that India currently lacks comparative advantage in several categories, for example, active pharmaceutical ingredient, medical equipment and devices, disinfectants and sterilisation products, and personal protective equipment. The country, however, enjoys a comparative advantage in manufacturing vaccines and formulations. Interestingly, India imposes higher tariffs and non-tariff measures (NTMs) on both sets of products, irrespective of the comparative advantages. Additionally, the article identifies important operational, logistic, and financial issues that can improve the efficiency of the pharmaceutical supply chain (PSC), which in turn can ensure smoother availability of these pharmaceutical products in the domestic market. While the operational issues underline the need for better coordination between multiple stakeholders, the logistic bottlenecks call for a general improvement at the infrastructure level. The financial issues correspond to infrastructural bottlenecks, transport costs and resulting cost escalation. The article concludes that the policymakers need to focus on the reduction of import barriers and improve the PSC to ensure the easier availability of COVID-19 medicines, vaccines, and related products. JEL Codes: F13, F15, I18, O25

Publisher

SAGE Publications

Subject

General Medicine

Reference40 articles.

1. The Recent Coronavirus (COVID-19) Pandemic: A Review of Issues for Indian Pharmaceutical Exports

2. Understanding the pharmaceutical value chain

3. Arora H. (2021). India has a vaccine hesitancy challenge. Indian Express. https://indianexpress.com/article/opinion/india-has-a-vaccine-hesitancy-challenge-7388907/

4. Trade Liberalisation and "Revealed" Comparative Advantage

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3